$2.52
4.55% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Annexon Inc Stock price

$2.52
+0.75 42.37% 1M
-2.36 48.36% 6M
-2.61 50.88% YTD
-2.94 53.85% 1Y
-15.24 85.81% 5Y
-15.24 85.81% 10Y
-15.24 85.81% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.12 4.55%
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Key metrics

Market capitalization $276.48m
Enterprise Value $12.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.13
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-182.91m
Free Cash Flow (TTM) Free Cash Flow $-139.88m
Cash position $263.70m
EPS (TTM) EPS $-1.13
P/E forward negative
Short interest 11.53%
Show more

Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Annexon Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

Buy
100%

Financial data from Annexon Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
26% 26%
-
- Research and Development Expense 147 147
43% 43%
-
-181 -181
40% 40%
-
- Depreciation and Amortization 2.15 2.15
0% 0%
-
EBIT (Operating Income) EBIT -183 -183
40% 40%
-
Net Profit -167 -167
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Annexon Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Glo...
Neutral
GlobeNewsWire
24 days ago
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations
Neutral
GlobeNewsWire
27 days ago
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 20...
More Annexon Inc News

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

Head office United States
CEO Douglas Love
Employees 100
Founded 2011
Website annexonbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today